Punjab, April 8 -- Milestones underscore clinical progress and strengthen commercial foundationLOS GATOS, Calif., April 8, 2026 /PRNewswire/ - Supira Medical, Inc.(Supira), a clinical-stage companyfocused on transforming the percutaneous ventricular assist device (pVAD) market, today announced FDA approval to initiate the SUPPORT II Pivotal Trial. The trial is designed to support a future PMA submission and represents a critical step toward U.S. market entry. SUPPORT II (SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)) is a prospective, randomized controlled study designed to assess the safety and efficacy of the company's next-generation pVAD in patients undergoing HRPCI. The study will enroll up t...